Polycystic ovary syndrome-Phenotypes and diagnosis

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 74, Issue SUPPL. 244, 2014, Pages 18-22

  Christakou, Charikleia ^a   Diamanti Kandarakis, Evanthia ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Lifecycle; Phenotypes; Polycystic ovary syndrome

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

CARDIOVASCULAR RISK; CONFERENCE PAPER; ENVIRONMENTAL FACTOR; HUMAN; INSULIN RESISTANCE; LIFE CYCLE; MORBIDITY; NUTRITION; OVARY POLYCYSTIC DISEASE; PHENOTYPE; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; STEROIDOGENESIS; BLOOD; FEMALE; HYPERANDROGENISM; POLYCYSTIC OVARY SYNDROME;

FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERANDROGENISM; PHENOTYPE; POLYCYSTIC OVARY SYNDROME;

EID: 84905374238     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2014.936675     Document Type: Conference Paper

References (26)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endo-crinol Metab 1999; 84: 4006-11.
2. Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med 2008; 10: e3.
3. Diamanti-Kandarakis E, Panidis D. Unravelling the pheno-typic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf) 2007; 67: 735-42.
4. Diamanti-Kandarakis E, Christakou C, Palioura E, et al. Does polycystic ovary syndrome start in childhood? Pediatr Endocrinol Rev 2008; 5: 904-11.
5. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications, 1992: 377-84.
6. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS): Hum Reprod 2004; 19: 41-7.
7. Azziz R CE, Dewailly D, Diamanti-Kandarakis E, et al. Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91: 456-88.
8. Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002; 13: 251-7.
9. Diamanti-Kandarakis, Christakou C, Marinakis E. Pheno-types and enviromental factors: their infl uence in PCOS. Curr Pharm Des 2012; 18: 270-82.
10. Tantalaki E, Piperi C, Livadas S, et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycys-tic ovary syndrome (PCOS). Hormones 2014; 13: 1-9.
11. Diamanti-Kandarakis E, Katsikis I, Piperi C, et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2008; 69: 634-41.
12. Jonard S, Rober t Y, Cortet-Rudelli C, et al. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod 2003; 18: 598-603.
13. Balen AH, Laven JS, Tan SL, et al. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003, 9: 505-14.
14. Broekmans FJ, Knauff EA, Valkenburg O, et al. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. Brit J Obstet Gynecol 2006; 113: 1210-17.
15. Rosenfield R. Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 787-96.
16. Shaw LJ, Bairey Merz CN, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Womens Ischemia Syndrome Evaluation. J Clin Endo-crinol Metab 2008; 93: 1276-84.
17. Yildiz BO, Bozdag G, Yapici Z, et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012; 27: 3067-73.
18. Rosner W, Auchus RJ, Azziz R, et al. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92: 405-413.
19. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 2009; 15: 477-88.
20. Dilbaz B, Ozkaya E, Cinar M, et al. Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. Endocrine 2011; 39: 272-7.
21. Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165-9.
22. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95: 2038-49.
23. Diamanti-Kandarakis E, Palioura E, Kandarakis SA, et al. The impact of endocrine disruptors on endocrine targets. Horm Metab Res 2010; 42: 543-52.
24. Palioura E, Diamanti-Kandarakis E. Industrial endocrine disruptors and polycystic ovary syndrome. J Endocrinol Invest 2013; 36(11): 1105-11.
25. Diamanti-Kandarakis E, Piouka A, Livadas S, et al. Anti-m ü llerian hormone is associated with advanced glycosy-lated end products in lean women with polycystic ovary syndrome. Eur J Endocrinol 2009; 160: 847.
26. Merhi Z. Advanced glycation end products and their relevance in female reproduction Hum Reprod 2014; 29: 135-45.